eyecro data to be presented at ARVO 2016 in Seattle


By combining data on optometry patient’s eyes with advanced computational methods, Indiana University researchers have created a virtual tissue model of diabetes in the eye. The results, reported in the journal PLOS Computational Biology, show precisely how a small protein that can both damage or grow blood vessels in the eye causes vision loss and…
Ophthalmic distribution studies indicate significantly increased drug concentration with CsA-MiDROPS (Cyclosporine A microemulsion) compared with Restasis. CsA-MiDROPS is well tolerated with little toxicity in a 2-week tolerability study. In the DED model, both 0.05% and 0.1% CsA-MiDROPS conferred a significant effect and were more effective than Restasis for treating experimental DED when dosed twice per…
Human-derived stem cells can spontaneously form the tissue that develops into the part of the eye that allows us to see, according to a study published by Cell Press in the 5th anniversary issue of the journal Cell Stem Cell. Transplantation of this 3D tissue in the future could help patients with visual impairments see…
“Anti-vascular endothelial growth factor (anti-VEGF) medications have a proven track record in treating diabetic macular edema (DME). However, researchers continue to investigate whether these medications can be made more efficient and cost-effective.” “Both the RETAIN[1] and REACT[2] studies showed that treat-and-extend regimens for ranibizumab were efficacious for DME. Further support was provided by the TREX-DME study, the first prospective, randomized controlled…
Conventional cancer treatments are accompanied by a host of side effects such as nausea and vomiting. The intensity of the side effects is many a time so acute that it poses a deterrent to further treatment. The reason behind the side effects is that existing cancer treatment methods do not address just the cancerous cells,…
A 20-year observational study has chronicled notable declines in retinopathy for young patients with type 1 diabetes who receive intensive glycemic control therapy, confirming earlier findings that found a link between normalized blood glucose levels and the slower progression of eye, kidney, and nerve damage. http://www.medscape.com/viewarticle/752133